Bigpharma Deals and Alliances of 2013


#187034

200pages

Current Partnering

$ 1495

In Stock

The Bigpharma Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013.
 
Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.
 
The initial chapters of this report provide an orientation of 2013’s dealmaking and business activities.
 
Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication.
 
Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. 
 
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2013.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013.

Key benefits
 
Bigpharma Deals and Alliances of 2013 provides the reader with the following key benefits:
                
  • In-depth understanding of recent dealmaking trends during 2013
  • Comprehensive access to all  deals entered into by the world’s biopharma companies during 2013
  • Detailed access to actual partnership and M&A deals and contracts entered into by the leading fifty bigpharma companies
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
 
Report scope
 
Bigpharma Deals and Alliances of 2013 is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.
 
Bigpharma Deals and Alliances of 2013 includes:
 
  • Trends in dealmaking in the biopharma industry during 2013
  • Analysis of partnering and M&A deal structure
  • Comprehensive directory of partnering and M&A deals in 2013
  • Links to online access to all deals and alliances
  • The leading partnering and M&A deals by value in 2013
  • Most active partnering and M&A dealmakers during 2013
 
In Bigpharma Deals and Alliances of 2013 the partnering and M&A deals are listed by:
 
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy area
  • Technology type
Table of Content

Executive Summary
 
Chapter 1 – Trends in dealmaking during 2013
1.1. Bigpharma dealmaking activity
1.2. Partnering by deal type
1.3. Partnering by industry sector
1.4. Partnering by stage of development           
1.5. Partnering by technology type
1.6. Partnering by therapy area
 
Chapter 2 – Leading deals during 2013
2.1. Introduction
2.2. Top deals by value during 2013
 
Chapter 3 – Bigpharma deals during 2013
3.1. Introduction
3.2. How to use bigpharma partnering deals
3.3. Bigpharma partnering company profiles for 2013
Abbott 
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene           
CSL     
Daiichi Sankyo
Dainippon Sumitomo
Eisai    
Eli Lilly
Endo Pharmaceuticals 
Forest Laboratories
Galderma        
Gilead Sciences           
GlaxoSmithKline          
Grifols 
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck         
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis          
Novo Nordisk
Otsuka
Pfizer  
Purdue
Roche 
Sanofi  
Servier
Shionogi
Shire   
Takeda
Teva   
Valeant
Warner Chilcott
Watson
 
Chapter 4 – Partnering deals directory 2013
4.1. Introduction           
4.2. Company A-Z        
4.3. By deal type
4.4. By stage of development
4.5. By technology type
4.6. By therapy area
                               
About Wildwood Ventures     

Current Partnering       
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form – Reports

Figure 1: Bigpharma – top 50 – January to December 2013
Figure 2: Bigpharma deal frequency – 2013
Figure 3: Partnering by deal type during 2013
Figure 4: Partnering by industry sector during 2013
Figure 5: Partnering by stage of development during 2013
Figure 6: Partnering by technology type during 2013
Figure 7: Partnering by therapy area during 2013
Figure 8: Top deals by value during 2013